Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PDE1B | Q01064 | 9/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PDE1A | P54750 | 2/20 | 0.42 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3586746 | 0.86 | SMN1; SMN2 (0.43) | SMN1; SMN2PDE1BALDH1A1MAPTHTT | |
| SCHEMBL3587206 | 0.83 | KDM4E (0.43) | PDE1BALDH1A1MAPTPDE1APDE1C | |
| SCHEMBL5317418 | 0.79 | ALDH1A1 (0.40) | SMN1; SMN2PDE1BALDH1A1MAPTHTT | |
| SCHEMBL3585667 | 0.78 | MEN1 (0.48) | SMN1; SMN2ALDH1A1MAPTMAPK1 | |
| SCHEMBL5317422 | 0.78 | NPC1 (0.46) | SMN1; SMN2ALDH1A1MAPTMAPK1TSHR | |
| SCHEMBL13349110 | 0.78 | PDE1B (0.37) | PDE1BALDH1A1MAPTPDE1APDE1C | |
| SCHEMBL1644934 | 0.70 | SMN1; SMN2 (0.49) | SMN1; SMN2TSHRHIF1AEPAS1 | |
| SCHEMBL17459011 | 0.70 | MEN1 (0.49) | ALDH1A1MAPT | |
| SCHEMBL3576115 | 0.68 | DCTPP1 (0.47) | SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL5755331 | 0.67 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1MAPTHTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | CDK1, CDK3, CDK13 | SMN1; SMN2 3277/4885PDE1B 3115/4885ALDH1A1 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.